A rare case of breast squamous cell carcinoma and literature review

Varughese, Bhirrinta; Sharif, Siti Zubaidah; Yee, Ho Kah; Lah, Nik Amin Sahid Nik

doi:10.1016/j.amsu.2022.103825

Cited by 1 publication

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management plans mostly adopt classical techniques for breast cancer management, consisting of surgery, chemotherapy, and radiotherapy [ 6 ]. Given its known aggressive behavior, upfront mastectomy with axillary clearance is the mainstream treatment, since most cases have nodal involvement [ 15 ]. It was previously believed that there was no role for neoadjuvant chemotherapy in breast SCC [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Breast SCC is very aggressive and has a poor prognosis, with a 5-year overall survival of 62.1% [ 19 ]. Poorer prognosis has been associated with having a larger tumor (larger than 3 cm), having nodal involvement, and the patient being a women below the age of 40 years old [ 15 , 20 ]. In our case, the tumor size was more than 3 cm, with 1 nodal involvement, and the patient’s age was 41 years old upon presentation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Case Report of a Rare ER+, PR- Pure Metaplastic Breast Squamous Cell Carcinoma with HER2 Overexpression

Adam,

Kamaruddin,

Abd Shukor

et al. 2023

Am J Case Rep

View full text Add to dashboard Cite

Patient: Female, 41-year-old Final Diagnosis: Pure metastatic squamous cell carcinoma of the breast Symptoms: Breast lump • liver metastasis • lung metastasis Clinical Procedure: Adjuvant hormone-therapy • adjuvant radiotherapy • axillary clearance • mastectomy • neoadjuvant chemotherapy • transverse rectus abdominis musculocutaneous (TRAM) flap Specialty: Family Medicine • Oncology • Pathology • Surgery Objective: Rare disease Background: Breast squamous cell carcinoma (SCC) is a subtype of metaplastic breast carcinoma (MBC), which is a rare malignancy and accounts for 0.1% of all invasive breast carcinomas. Guidelines on definitive management and treatment of breast SCC are not well established, given its rarity and diverse immunohistochemistry (IHC) profile, and lack of clinical data. Most cases of breast SCC are triple-negative breast cancer – negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This case report outlines the clinicopathological profile of a pure breast SCC case with a rare IHC profile; HER2 and ER positive. Case Report: A 41-year-old woman presented with a right breast mass that had been growing for 2 months. Biopsy confirmed breast SCC, a rare malignancy with IHC profile as follows: HER2 overexpression, ER positive, and PR negative. She underwent neoadjuvant chemotherapy for 3 months followed by right mastectomy with axillary clearance, adjuvant radiotherapy, and oral tamoxifen therapy. Unfortunately, she did not receive anti-HER2 therapy. She developed early locoregional recurrence at 2 months postoperatively, which was treated with excision of the right chest wall and transverse rectus abdominis musculocutaneous (TRAM) flap. She developed liver and lung metastasis and succumbed to her disease at 15 months post-diagnosis. Conclusions: Breast SCC is a rare and aggressive tumor with heterogeneous clinicopathological features. Available guidelines do not outline the definitive treatment for breast SCC, given its rarity and heterogenous IHC profile, leading to a general lack of clinical data. Hence, due to the challenges in managing this rare condition, treatment modalities need to be individualized.

show abstract

Section: Discussionmentioning

confidence: 99%